tbuckley/cabot-search huggingface dataset:
Effect of Neuraminidase on Tumor Development and Growth: Reply
Authors: L. Weiss
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Effect of Neuraminidase on Tumor Development and Growth: Reply Get access L. Weiss L. Weiss Department of Experimental Pathology Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 4, October 1973, Pages 1394–1395, https://doi.org/10.1093/jnci/51.4.1394 Published: 01 October 1973
Advanced Stage Hodgkin’s Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era
Authors: Jose-Tomas Navarro, Marc Sorigue, Blanca Xicoy, Olga Garcia, Maria Joao Baptista, Juan-Manuel Sancho, Jose-Luis Mate, Evarist Feliu, Josep-Maria Ribera
Journal: Blood (2014)
A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN
Authors: Yang Liu, Ali Tabarroki, Valeria Visconte, Edy Hasrouni, Manoj Bupathi, Betty K. Hamilton, Fabiola Traina, Hien K. Duong, Heesun J. Rogers, Yogen Saunthararajah, Rami S. Komrokji, Mikkael A. Sekeres, Ramon V. Tiu
Journal: Blood (2012)
Distinctive Genetic Features of Plasma Cells in POEMS Syndrome
Authors: Yuhei Nagao, Naoya Mimura, June Takeda, Motohiko Oshima, Kenichi Yoshida, Yusuke Shiozawa, Kazumasa Aoyama, Atsunori Saraya, Shuhei Koide, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Chika Kawajiri-Manako, Nagisa Hasegawa, Shio Sakai, Yusuke Takeda, Chikako Ohwada, Masahiro Takeuchi, Emiko Sakaida, Tohru Iseki, Sonoko Misawa, Koutaro Yokote, Satoru Miyano, Osamu Ohara, Satoshi Kuwabara, Masashi Sanada, Atsushi Iwama, Seishi Ogawa, Chiaki Nakaseko
Journal: Blood (2016)
Prediction of the treatment response to eribulin chemotherapy in breast cancer using tumor-infiltrating lymphocytes
Authors: Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Kento Kurata, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Masahiko Ohsawa, Masaichi Ohira, Kosei Hirakawa
Journal: Annals of Oncology (2016)
Development and Internal Validation of a Clinical Risk Score for Treating Children With Mild Head Trauma and Intracranial Injury
Authors: Jacob K. Greenberg, Yan Yan, Christopher R. Carpenter, Angela Lumba-Brown, Martin S. Keller, Jose A. Pineda, Ross C. Brownson, David D. Limbrick
Journal: JAMA Pediatrics (2017)

<h3>Importance</h3> The appropriate treatment of children with mild traumatic brain injury (mTBI) and intracranial injury (ICI) on computed tomographic imaging remains unclear. Evidence-based risk assessments may improve patient safety and reduce resource use. <h3>Objective</h3> To derive a risk score predicting the need for intensive care unit observation in children with mTBI and ICI. <h3>Design, Setting, and Participants</h3> This retrospective analysis of the prospective Pediatric Emergency Care Applied Research Network (PECARN) head injury cohort study included patients enrolled in 25 North American emergency departments from 2004 to 2006. We included patients younger than 18 years with mTBI (Glasgow Coma Scale [GCS] score, 13-15) and ICI on computed tomography. The data analysis was conducted from May 2015 to October 2016. <h3>Main Outcomes and Measures</h3> The primary outcome was the composite of neurosurgical intervention, intubation for more than 24 hours for TBI, or death from TBI. Multivariate logistic regression was used to predict the outcome. The C statistic was used to quantify discrimination, and model performance was internally validated using 10-fold cross-validation. Based on this modeling, the Children's Intracranial Injury Decision Aid score was created. <h3>Results</h3> Among 15 162 children with GCS 13 to 15 head injuries who received head computed tomographic imaging in the emergency department, 839 (5.5%) had ICI. The median ages of those with and without a composite outcome were 7 and 5 years, respectively. Among those patients with ICI, 8.7% (n = 73) experienced the primary outcome, including 8.3% (n = 70) who had a neurosurgical intervention. The only clinical variable significantly associated with outcome was GCS score (odds ratio [OR], 3.4; 95% CI, 1.5-7.4 for GCS score 13 vs 15). Significant radiologic predictors included midline shift (OR, 6.8; 95% CI, 3.4-13.8), depressed skull fracture (OR, 6.5; 95% CI, 3.7-11.4), and epidural hematoma (OR, 3.4; 95% CI, 1.8-6.2). The model C statistic was 0.84 (95% CI, 0.79-0.88); the 10-fold cross-validated C statistic was 0.83. Based on this modeling, we developed the Children's Intracranial Injury Decision Aid score, which ranged from 0 to 24 points. The negative predictive value of having 0 points (ie, none of these risk factors) was 98.8% (95% CI, 97.3%-99.6%). <h3>Conclusions and Relevance</h3> Lower GCS score, midline shift, depressed skull fracture, and epidural hematoma are key risk factors for needing intensive care unit–level care in children with mTBI and ICI. Based on these results, the Children's Intracranial Injury Decision Aid score is a potentially novel tool to risk stratify this population, thereby aiding management decisions.
PRPF8 Defects Cause Missplicing In Myeloid Malignancies
Authors: Amina Kurtovic Kozaric, Hideki Makishima, Bartlomiej P Przychodzen, Jarnail Singh, Magda Maria Konarska, Zaher K. Otrock, Megan Nakashima, Eric D. Hsi, Kenichi Yoshida, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2013)
Clinical validation of photochemical internalisation (fimaVacc) – A novel technology for enhancing cellular immune responses to peptide- and protein-based therapeutic cancer vaccines
Authors: A. Høgset, T. Otterhaug, L. Wabakken, K. Eivindvik, L. Finnesand, K. Nord, P. Walday
Journal: Annals of Oncology (2016)
Review: Innate Lymphoid Cells: Sparking Inflammatory Rheumatic Disease?
Authors: Mark H. Wenink, Emmerik F. A. Leijten, Tom Cupedo, Timothy R. D. J. Radstake
Journal: Arthritis & Rheumatology (2017)

Immunology research is in a constant state of flux with new cell types being described on a regular basis. While most rheumatologists are familiar with the role that “T cell cytokines” such as tumor necrosis factor (TNF), interferon-g (IFNg), and interleukin-17A (IL- 17A) play in the pathogenesis of rheumatic diseases, what many may not know is that an array of innate counterparts to the conventional T cells have recently been discovered that are capable of rapidly producing these same effector cytokines. These innate counterparts include g/d T cells, invariant natural killer (iNK) cells, mucosa-associated invariant T (MAIT) cells, and innate lymphoid cells (ILCs). An insightful overview of g/d T cells, iNK cells, and MAIT cells in rheumatic disease has recently been published (1); therefore, the current review focuses on ILCs. Strikingly, some of the ILCs have only recently been discovered, in part due to their relative scarcity in peripheral blood, and their presence in numerous organs of the human body has subsequently been described. In this review, we provide the newest insights into the potential role of ILCs in the field of rheumatology and provide recommendations for future ILC research that will help to promote our understanding of rheumatic diseases even further.
Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.
Authors: Karl J. Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Anna Vales, Sophia Derdak, Winfried F. Pickl, Edgar Selzer, Michael Deininger, Brian J. Druker, Christian Sillaber, Peter Valent
Journal: Blood (2005)
Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.
Authors: Andrea Rinaldi, Michael Mian, Davide Rossi, Francesco Forconi, Clara Deambrogi, Valeria Spina, Emanuele Cencini, Elisa Sozzi, Daniela Drandi, Marco Ladetto, Rita Santachiara, Roberto Marasca, Ekaterina Chigrinova, Franco Cavalli, Valter Gattei, Emanuele Zucca, Gianluca Gaidano, Ivo Kwee, Francesco Bertoni
Journal: Blood (2009)
Enhancement of Soluble Transcription Factor (TAT-HOXB4 and TAT-NUP98HOXA10HD) - Mediated Human Hematopoietic Stem Cell Self-Renewal by Minimizing Inhibitory Endogenous Signalling.
Authors: Elizabeth Csaszar, Daniel Kirouac, Genevieve Gavigan, Suzan Imren, Michelle Miller, R. Keith Humphries, Peter W. Zandstra
Journal: Blood (2009)
Unexpected Functional Consequences of the Loss of the Autophagy-Related Conjugation System
Authors: Toshiro Saito, Junichi Sadoshima
Journal: Circulation Research (2017)

We discuss the recent finding by Mizishima's group regarding the role of the autophagy-related conjugation system in mediating the closure of autophagosomes and its implication in the study of autophagy in mammalian cells. The study not only shows a novel function of the autophagy-related conjugation system but also indicates that mammalian cells are capable of generating autophagosomes even without it.
ACTR-51. PRELIMINARY SUPPORT FOR 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN) AS A CHEMOSENSITIZER IN CANCERS INVOLVING THE CNS
Authors: Marcus Ware, Roy Weiner, Tallat Mahmood, Ronald Kawauchi, AH Rogers, Lee Roy Morgan, Kiran Devisetty, Jay Jiguang Zou, Manish Bhandari, Robert Summe, James Herman, Judy Weber
Journal: Neuro-Oncology (2016)

DM-CHOC-PEN is a poly-chlorinated pyridine cholesteryl carbonate that has completed a Phase I/II study [AACR #1185, 2013; #CT129, 2016] in subjects with primary brain cancers and metastatic cancers involving the CNS. We review clinical and in vitro data that support radiosensitizing properties of DM-CHOC-PEN. DM-CHOC-PEN was administered as a 3-hr IV infusion once every 21 days. The Phase II dose schedule was 2-tiered: 85.8 mg/m2 for subjects with liver involvement and 98.7 mg/m2 for subjects with normal livers. In vitro, human NSCLC adenocarcinoma cells (H-2086) growing in culture (106 cells/mL) were pre-treated with DM-CHOC-PEN (0.1 -1.0 µg/mL) for 24 hrs, drug washed, re-fed fresh medium and then 48 h later irradiated (RT @ 6, 9, 12 Gy). Fifty three (53) subjects have been treated to date. Five (5) subjects (3-NSCLC & 2-sarcomas) required surgery for persistent CNS lesions. DM-CHOC-PEN was identified in all samples. Two of those 5-subjects (1-sarcoma/1-NSCLC) plus 4 - additional subjects with persistent NSCLC lesions involving the CNS were treated then received SRS or WBRT. All had excellent results (OS 8+ - 26+ mos). Support from in vitro studies was: for DM-CHOC-PEN (0.1 -1.0 µg/mL) – cell kill was 50 & 100% @ 0.4 & 1.0 µg/mL, resp.; for RT (6, 9 &12 Gy) – cell kill was 20 & 65% @ 6 & 12 Gy, resp. [100% kill was not observed @ this dose range]; for DM-CHOC-PEN (0.25 µg/mL) + RT (6–12 Gy) – Cell kill was 80 & 100% @ 6 & 12 Gy, resp. Thus, in combination – less drug (0.25 µg/mL) and RT of 12 Gy – produced a 100% cell kill. DM-CHOC-PEN may act as cytotoxic drug for cancer in the CNS that is also a radiosensitizer.
APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy
Authors: K. Yamaguchi, Y. Komatsu, E. Oki, T. Yoshino, K. Yamazaki, K. Shibuya, K. Oba, T. Kato
Journal: Annals of Oncology (2016)
Predicting Clinical Outcome in Patients with Idiopathic Thrombocytopenic Purpura Based on Bone Marrow Clot CD20+ Lymphocytes.
Authors: Shingo Kurahashi, Hiroto Narimatsu, Masafumi Ito, Fumiko Yamamoto, Akiyo Sawamoto, Tatsuya Adachi, Isamu Sugiura
Journal: Blood (2006)
Molecular Characterization of Unique Junctional Complexes as Communication Pathways among Mesenchymal Stem Cells.
Authors: Patrick Wuchter, Judit Boda-Heggemann, Beate Straub, Ulf Krause, Anja Seckinger, Caecilia Kuhn, Christine Grund, Sandra Gottschling, Werner W. Franke, Anthony D. Ho
Journal: Blood (2005)
MPTH-02. EXTRACELLULAR EGFR289 ACTIVATING MUTATIONS CONFER POORER SURVIVAL AND SUGGEST ENHANCED MOTILITY IN PRIMARY GBMs
Authors: Zev Binder, Spyridon Bakas, E. Paul Wileyto, Hamed Akbari, Saima Rathore, Martin Rozycki, Jennifer J.D. Morrissette, Maria Martinez-Lage, Nadia Dahmane, Christos Davatzikos, Donald O’Rourke
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common adult, malignant, primary brain tumor. Approximately 60% of GBMs harbor an EGFR alteration. The most common alteration is amplification, followed by the EGFR variant III mutation (EGFRvIII), and then various point mutations. We examined a retrospective cohort of GBM patients operated on at the Hospital of the University of Pennsylvania for point mutations in EGFR and assessed their correlation with clinical outcomes and advanced radiographic imaging. Here we report a negative survival correlation with a substitution of alanine at residue 289 (A289) and advanced magnetic resonance imaging (MRI) features associated with the presence of an A289 point mutation. These multi-parametric features suggested a radiographic signature of more aggressively infiltrating and proliferating tumors when compared to imaging from patients without an A289 point mutation. Additionally, several features were distinct from a previously developed EGFRvIII advanced MRI signature. Taken together, these data reveal that the A289 mutation may identify a subset of GBMs with poor survival and a specific advanced MRI signature suggestive of enhanced motility and invasion.
Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia
Authors: Christian Hurtz, Lai N Chan, Erica Ballabio, Cheryl L. Willman, William L. Carroll, Scott A. Armstrong, Patricia Ernst, Ari Melnick, Thomas Milne, Markus Müschen
Journal: Blood (2016)
A Population-Based Study In Acute Myeloid Leukemia (AML) Suggests Improved Overall Survival (OS) up to Age 80 with Intravenous Therapy: 2000–2007 Data From the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry In the United States (US),
Authors: Betul Oran, Daniel J. Weisdorf, Beth Virnig
Journal: Blood (2011)
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results
Authors: M.A. Fabbri, C.N. Sternberg, E. Cortesi, D. Santini, G. Procopio, M. Paolo, T. Gamucci, P. Carlini, M. Roselli, F. Longo, G. Schinzari, M. De Tursi, G. Lanzetta, A. Pellegrino, A. Milano, I. Sperduti, M.L. Mancini, F. Primi, E.M. Ruggeri
Journal: Annals of Oncology (2016)
RTHP-15. NEURAL STEM CELL NICHE INVOLVEMENT AND PATTERNS OF FAILURE IN GLIOBLASTOMA MULTIFORME
Authors: Rimpa Basu Achari, Animesh Saha
Journal: Neuro-Oncology (2016)

To evaluate the impact of magnetic resonance imaging (MRI) dynamics of glioblastoma, in context of pre and post treatment involvement of the neural stem cell compartment (NSC) on progression free (PFS) and overall survival (OS). Baseline and followup MRI images were serially evaluated in 61 patients treated with standard post resection chemoradiation and temozolomide between 2011 to 2015. MRI morphology groups were based on any combination(s) of NSC involvement, cortical involvement or both by contrast enhancing lesions (CELs). MRI images at recurrence were registered with the radiation treatment planning datasets in order to assess the patterns of failure in context of the previously contoured NSC volumes. With a median followup of 14.1 months (interquartile range 9.4 – 20.6 months), the median [95% confidence interval (CI)] PFS and OS were 14.5 (95% CI 11.6 – 17.5 months) and 16.2 (95% CI 13.3 – 19.2 months) months, respectively. Baseline involvement of NSC with CELs with varying degrees of cortical involvement was seen in 41/61 patients. At progression, 95.9% patients had progressive involvement of previously contoured NSC with CELs and FLAIR abnormalities. In patients with CELs involving the NSC at presentation, log-rank univariate analyses revealed a non significant decline in PFS (13.01 vs 15.18 months, p = 0.51) and OS (14.62 vs 17.08 months, p = 0.62). However, there was a significantly higher chance of distant brain progression (40.5%, p = 0.05) and multifocal progression (36%, p = 0.05) in patients with pretreatment NSC involvement with CELs compared to those without. In our cohort, pre treatment NSC involvement was associated with a significantly higher incidence of distant brain failure and multifocal recurrences. Though it did not reach significance, baseline NSC involvement might be associated with inferior PFS and OS. Prospective validation in a larger cohort is necessary.
Sites of gastric cancer recurrence after adjuvant chemoradiotherapy.
Authors: T. Conrad, S. MacLellan, Z. Kassam, H. Mackay, I. Khalili, L. M. Jacks, A. Okrainec, J. Ringash
Journal: Journal of Clinical Oncology (2011)

68 Background: Since the Intergroup 0116 study in 2000, adjuvant post-operative chemoradiotherapy (CRT) has been offered routinely to similar patients with resected gastric cancer at Princess Margaret Hospital (PMH) using CT-planned and 3D conformal/intensity modulated radiotherapy (RT). The objective of this study was to analyze patterns of recurrence with respect to RT treatment volumes. Methods: Date and site (local, locoregional or distant) of first recurrence data was obtained from chart review for all patients treated at PMH with adjuvant CRT for resected gastric adenocarcinoma (Jan. 1, 2000-Nov. 30, 2009). Patients whose recurrences were limited to local (gastric remnant, duodenal margin, gastric bed recurrence) and/or regional sites (regional lymph node recurrence) were selected for analysis. When available, diagnostic imaging of recurrence site was registered to the original planning RT dataset. The center of mass for each recurrence was identified as a point and its location categorized according to the isodose encompassing it; in-field (≥ 90%), marginal (50%-89%), and out-of-field (&lt; 50%). Results: Three-year OS, and RFS were 66% (95% CI: 58-73) and 58% (50-60), respectively. Of 203 patients treated, 75 recurrences were identified (Table). Of the 13 local/locoregional recurrences, 4 were in-field, 1 marginal, 1 could not be registered due to change in body habitus, and 7 did not have an available original dataset. Conclusions: Rates of isolated local and/or regional recurrence in this study were low. This represents a change in the pattern seen with surgery alone suggesting the addition of CRT results in decreased isolated local and/or regional recurrence. Of the small number of local and/or regional recurrences available for analysis, all were in-field or marginal. Further studies involving a larger cohort of patients might allow for more meaningful analysis of trends in recurrence site with evolving RT techniques. [Table: see text] No significant financial relationships to disclose.
Sixty seconds on . . . swine flu vaccine
Authors: Anne Gulland
Journal: BMJ (2017)

Fortunately not, but it’s in the news because of a High Court ruling that could mean the government having to make big payouts to children who developed narcolepsy after vaccination against swine flu.

A boy called “John,” now 14 years old, received the Pandremix vaccine in December 2009, when the A/H1N1 swine flu pandemic was in …
Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC)
Authors: E. Kilgour, H. Angell, K.-M. Kim, S. Ahn, S.T. Kim, A. Sharpe, J. Ogden, A. Davenport, J.C. Barrett, D. Hodgson, J. Lee
Journal: Annals of Oncology (2016)
P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
Authors: S. Koeppen, J. Hense
Journal: Neuro-Oncology (2016)

AbstractThe prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS). A 45-year-old female who underwent surgery for left fronto-temporal WHO grade II astrocytoma associated with epilepsy in 2005, 125I seed implantation at disease progression in 2009 and seed explantation 9 months later, was diagnosed with MGMT methylated GBM on the occasion of partial tumor resection in 2010 followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) chemotherapy, which was stopped after 4 months due to resection of a left temporal tumor cyst and recurrent cyst within 1 month. TMZ treatment causing prolonged thrombocytopenia was discontinued after 1 additional cycle. Immediately after this cycle, the patient experienced left median cerebral artery stroke resulting in right hemianopia, Broca’s aphasia and severe hemiparesis of the right side. Three months later, BEV 10 mg/kg i.v. q14d was initiated, shortly interrupted for abdominal herniotomy in 2012, and continued for 3 years. Since 2014, concurrent low molecular weight heparin was given because of right lower limb deep venous thrombosis suspicion. Whereas GBM progression had not been detected for 2 years during anti-VEGF therapy, methionine PET MRI 6 months after BEV discontinuation revealed left temporal tumor recurrence. Rechallenge with BEV was initiated and the patient remained in stable clinical and radiographical condition for 10 months until now. This case highlights the utility of sequential BEV treatment in a patient being at high risk to develop chemotherapy-induced myelotoxicity. Long-term survival (> 3 years after diagnosis) in GBM has been attributed to patient-derived rather than tumor-derived factors. To our knowledge, this is the first description of effective long-term monotherapy with BEV for GBM and ongoing therapeutic response to single-agent BEV rechallenge in a patient with recurrent secondary GBM.
The Prognostic Relevance of Comprehensive Risk Score Is Modulated By Therapy: Analysis of 292 Acute Myeloid Leukemia Patients Registered at the Genova Acute Leukemia Registry (REGAL)
Authors: Fabio Guolo, Paola Minetto, Elena Clavio, Giordana Pastori, Daniela Guardo, Lisette Del Corso, Chiara Ghiggi, Maurizio Miglino, Germana Beltrami, Angelo Michele Carella, Roberto Massimo Lemoli, Andrea Bacigalupo, Marco Gobbi, Marino Clavio
Journal: Blood (2015)
Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy
Authors: Susanne Schnittger, Wolfgang Kern, Tamara Weiss, Claudia Tschulik, Frank Dicker, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2008)
Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Annalisa Chiappella, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Giovannino Ciccone, Flavia Salvi, Emanuele Angelucci, Barbara Botto, Antonella Darbesio, Roberto Freilone, Lorella Orsucci, Vincenzo Pavone, Enrico Maria Pogliani, Umberto Ricardi, Delia Rota-Scalabrini, Anna Tonso, Alessandra Tucci, Eugenio Gallo, Umberto Vitolo
Journal: Blood (2007)
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma
Authors: R. Dummer, O.A. Michielin, M. Nägeli, S.M. Goldinger, F. Campigotto, U. Kriemler-Krahn, H. Schmid, A. Pedroncelli, S. Micaletto, D. Schadendorf
Journal: Annals of Oncology (2016)